Advisory Research’s AEON Biopharma AEON Stock Holding History

Advisory Research’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-662	Closed	-$479K	–	352
2022 Q4	$479K	Hold	662	–	–	0.05%	252
2022 Q3	$469K	Hold	662	–	–	0.05%	242
2022 Q2	$468K	Sell	662 -1,404	-68%	-$991K	0.05%	236
2022 Q1	$1.46M	Hold	2,066	–	–	0.12%	146
2021 Q4	$1.44M	Buy	2,066 +40	+2%	+$28.1K	0.11%	160
2021 Q3	$1.42M	Hold	2,026	–	–	0.09%	162
2021 Q2	$1.41M	Buy	+2,026	New	+$1.42M	0.09%	175

Other funds holding AEON

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

GCWM

Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Advisory Research's AEON Position: Q1 2023 in Review

Advisory Research sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 662 shares — an estimated $479K sold.

Advisory Research first reported a position in AEON in Q2 2021 and held it in 7 quarters. The position peaked at $1.46M in Q1 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

Advisory Research reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
Advisory Research sold 662 AEON Biopharma shares in Q1 2023, an estimated $479K.
Advisory Research first reported a position in AEON Biopharma in Q2 2021 and held it in 7 quarters.
Advisory Research's AEON Biopharma position peaked at $1.46M in Q1 2022.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Advisory Research's 13F filing for Q1 2023, filed 12 May 2023.